1199-0378 InPedILD™-ON
Research type
Research Study
Full title
An open-label trial of the long-term safety and tolerability of nintedanib per os, on top of standard of care, over at least 2 years, in children and adolescents with clinically significant fibrosing Interstitial Lung Disease (InPedILD™-ON)
IRAS ID
302533
Contact name
Steve Cunningham
Contact email
Sponsor organisation
Boehringer Ingelheim Ltd
Eudract number
2020-005554-23
Clinicaltrials.gov Identifier
Duration of Study in the UK
4 years, 1 months, 26 days
Research summary
Childhood interstitial lung disease ‘ILD’ syndrome is a term used to describe lung disease in children with non-specific respiratory symptoms. It includes a group of respiratory diseases that are associated with chronic fibrosis (scarring of the lung tissue). There are no currently approved therapies for the treatment of ILD in children. Nintedanib is a study drug that aims to reduce fibrosis in the lungs. It is currently being used in a trial to test the safety of nintedanib in children (the InPedILD™ study). The aim of this current study is to test the long-term safety of nintedanib in children with fibrosing ILD, for at least 2 years. Children and adolescents with clinically significant fibrosing ILD will be invited to take part in this trial, including those who have completed the InPedILD™ study.
REC name
London - Brent Research Ethics Committee
REC reference
21/LO/0814
Date of REC Opinion
10 Jan 2022
REC opinion
Further Information Favourable Opinion